Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.137NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.446NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.446NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.76 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.76 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.398NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.398NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.163NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.163NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.3 (Theta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
P.3 (Theta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.38.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.38.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAVNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XAVNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.1.4.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BE.1.4.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.1.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBC.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.362.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.362.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.162NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.162NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Y.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Y.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.86NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.86NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.154NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.154NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.4.8NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.4.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1.1.21NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CH.1.1.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26074.3US
AZ.5NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AZ.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.193NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.193NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22381.5US
BL.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BL.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FP.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FP.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DA.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
DA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.439NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.439NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.408NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.408NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.256NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.256NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Q.7 (Alpha)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used